作为SGLT2抑制剂的达帕格利弗洛辛在糖原储存疾病XI中改善了功能
Francesco Trepiccione1,2, Anna Iervolino1,2, Mariavittoria D'Acierno2
1Department of Medical Translational Sciences, University of Campania "Luigi Vanvitelli," 80131 Naples, Italy.
Science translational medicine
|November 1, 2023
概括
由于GLUT2缺陷,Fanconi-Bickel综合征 (FBS) 导致功能障碍. 作为SGLT2抑制剂的达帕格利弗洛辛 (Dapagliflozin) 减少了糖原的积累,并改善了小鼠和患者的症状,为FBS提供了潜在的治疗方法.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 糖原储存疾病XI (Fanconi-Bickel综合征,FBS) 是一种罕见的遗传疾病.
- 它是由SLC2A2基因的突变引起的,影响葡萄糖转运体2型 (GLUT2).
- 患者患有严重的近管功能障碍,没有有效的治疗.
研究的目的:
- 为了研究Fanconi-Bickel综合征的病变.
- 探索GLUT2在近端管细胞恒温中的作用.
- 评估达帕格利弗洛辛作为FBS的潜在治疗剂.
主要方法:
- 创建了一个小鼠模型,具有脏特异性的SLC2A2剥离.
- 在体外研究中利用了HK-2近端管细胞.
- 向小鼠注射达帕格利弗洛辛,并治疗了一名FBS患者.
主要成果:
- 在小鼠中,GLUT2缺乏导致糖原积累和Fanconi表型.
- 在实验室中观察到 lysosomal autophagy 功能受损,低葡萄糖逆转.
- 在小鼠中,达帕格利弗洛辛治疗降低了糖原,纠正了代谢酸和酸尿.
- 达帕格利弗洛辛在FBS患者中显示出安全性和有效性,改善了电解质水平并减少了葡萄糖尿.
结论:
- GLUT2在预防葡萄糖毒性和维持近接管道平衡方面发挥着至关重要的作用.
- 用达帕格利弗洛辛等SGLT2抑制剂准近接管道葡萄糖的流入,对治疗Fanconi-Bickel综合征有很大的前景.
- 达帕格利弗洛辛代表了FBS的潜在治疗策略,需要进一步的临床研究.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
01:24Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
01:06Oral Hypoglycemic Agents: Glinides
159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159
01:27Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183